| |OCTOBER 202619India Pharma Outlook's November Special - 2026: The edition has been prepared after being closely scrutinized by a distinguished panel of judges including CXOs, analysts, and our editorial board. We recognize their valuable contribution to the ever expanding and competitive market and their ability to sustain themselves and emerge as top contestants through their reliable products and solutions."Biophilin works with approximately 1,500 doctors, has a team of around 35 employees and supplies products to more than 25 hospitals in Bengaluru" - BIOPHILIN PHARMACEUTICALS"As a direct manufacturer, Dhanya sees the ability to provide customers with both competitive economics and direct access to technical expertise as an important advantage" - DHANYA BIO LIFE SCIENCES"Over time, Sripath intends to evolve this approach from conventional wound care towards what it describes as `innovative accelerated repair', eventually encompassing internal wounds as well" - NISHE THERAPEUTICS"Saher Technologies' evolution has been guided by an understanding that medical device manufacturers ultimately require a reliable production process, not merely a piece of machinery" - SAHER TECHNOLOGIES"Shasunmed sees the opportunity for fermentation extending well beyond a single pharmaceutical application" - SHASUNMED"The foundation of Suria Eye Products is closely connected to extensive work in pharmaceutics and advanced drug delivery" - SURIA EYE PRODUCTS"Zinnia expects cardiometabolic management to become increasingly integrated as cardiovascular disease, diabetes, obesity, renal health and metabolic disorders converge" - ZINNIA LIFE SCIENCESLet's delve more into these prominent players and know how they are spearheading the industry today.
< Page 9 | Page 11 >